Akhila Balakrishna Rai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Akhila Balakrishna Rai has a total of 59 co-authors. Here are the top co-authors by number of shared publications:
- Thotterthodi Subrahmanya Keshava Prasad
Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore, Karnataka, India
8 shared publications - Bipasha Bose
Stem Cells and Regenerative Medicine Centre, Yenepoya Research Centre Yenepoya (Deemed to be University) Mangalore Karnataka India
2 shared publications - Giridhara Prema Suchitha
Center for Systems Biology and Molecular Medicine, Yenepoya Research Centre, Yenepoya (Deemed to be University), Mangalore 575018, India
2 shared publications - Rachit Agarwal
Department of Bioengineering, Indian Institute of Science, Bengaluru, India
2 shared publications - Rajesh Raju
Centre for Integrative Omics Data Science (CIODS), Yenepoya (Deemed to be University), Mangalore 575018, Karnataka, India
2 shared publications - Rajesh Yadav
Indian Institute of Science, Bengaluru, India
2 shared publications
Latest Publications
- Open Access
- 8 June 2026
- Published by Springer Nature in Research Square
Broad heterologous protection against Influenza A viruses by an adjuvant-free modular mucosal T-cell vaccine platform.
Rapid antigenic evolution of Influenza A viruses (IAVs) enables their escape from strain-specific vaccine immunity and underscores the need for broadly protective strategies. Here, we describe a modular, adjuvant-free mucosal vaccine platform that elicits potent and cross-protective T cell immunity. The approach uses overlapping CD4+ and CD8+ epitope-dense regions from the consensus IAV M1 and NP proteins, identified through computational and functional screening. These peptides are delivered using polylactic-co-glycolic acid (PLGA) microparticles, engineered for selective uptake by antigen-presenting cells and enable sustained, pH-responsive antigen release. This design enhances antigen processing and MHC cross-presentation, functionally substituting for a conventional adjuvant. This formulation drives robust activation of primed human as well as murine CD4+ and CD8+ T cells and confers broad protection against homologous (H1N1, H3N2) as well as heterologous (H5N1) IAV strains in immunized mice. Overall, this adjuvant-free dose-sparing platform establishes an adaptable framework for next-generation broadly-protective vaccines against rapidly-evolving viruses.
- 8 June 2026
- Published by Springer Nature in Research Square
Open AccessBroad heterologous protection against Influenza A viruses by an adjuvant-free modular mucosal T-cell vaccine platform.
Rapid antigenic evolution of Influenza A viruses (IAVs) enables their escape from strain-specific vaccine immunity and underscores the need for broadly protective strategies. Here, we describe a modular, adjuvant-free mucosal vaccine platform that elicits potent and cross-protective T cell immunity. The approach uses overlapping CD4+ and CD8+ epitope-dense regions from the consensus IAV M1 and NP proteins, identified through computational and functional screening. These peptides are delivered using polylactic-co-glycolic acid (PLGA) microparticles, engineered for selective uptake by antigen-presenting cells and enable sustained, pH-responsive antigen release. This design enhances antigen processing and MHC cross-presentation, functionally substituting for a conventional adjuvant. This formulation drives robust activation of primed human as well as murine CD4+ and CD8+ T cells and confers broad protection against homologous (H1N1, H3N2) as well as heterologous (H5N1) IAV strains in immunized mice. Overall, this adjuvant-free dose-sparing platform establishes an adaptable framework for next-generation broadly-protective vaccines against rapidly-evolving viruses.
- Open Access
Broad heterologous protection against Influenza A viruses by an adjuvant-free modular mucosal T-cell vaccine platform
Rapid antigenic evolution of Influenza A viruses (IAVs) enables their escape from strain-specific vaccine immunity and underscores the need for broadly protective strategies. Here, we describe a modular, adjuvant-free mucosal vaccine platform that elicits potent and cross-protective T cell immunity. The approach uses overlapping CD4+ and CD8+ epitope-dense regions from the consensus IAV M1 and NP proteins, identified through computational and functional screening. These peptides are delivered using polylactic-co-glycolic acid (PLGA) microparticles, engineered for selective uptake by antigen-presenting cells and enable sustained, pH-responsive antigen release. This design enhances antigen processing and MHC cross-presentation, functionally substituting for a conventional adjuvant. This formulation drives robust activation of primed human as well as murine CD4+ and CD8+ T cells and confers broad protection against homologous (H1N1, H3N2) as well as heterologous (H5N1) IAV strains in immunized mice. Overall, this adjuvant-free dose-sparing platform establishes an adaptable framework for next-generation broadly-protective vaccines against rapidly-evolving viruses. Graphical
Open AccessBroad heterologous protection against Influenza A viruses by an adjuvant-free modular mucosal T-cell vaccine platform
Rapid antigenic evolution of Influenza A viruses (IAVs) enables their escape from strain-specific vaccine immunity and underscores the need for broadly protective strategies. Here, we describe a modular, adjuvant-free mucosal vaccine platform that elicits potent and cross-protective T cell immunity. The approach uses overlapping CD4+ and CD8+ epitope-dense regions from the consensus IAV M1 and NP proteins, identified through computational and functional screening. These peptides are delivered using polylactic-co-glycolic acid (PLGA) microparticles, engineered for selective uptake by antigen-presenting cells and enable sustained, pH-responsive antigen release. This design enhances antigen processing and MHC cross-presentation, functionally substituting for a conventional adjuvant. This formulation drives robust activation of primed human as well as murine CD4+ and CD8+ T cells and confers broad protection against homologous (H1N1, H3N2) as well as heterologous (H5N1) IAV strains in immunized mice. Overall, this adjuvant-free dose-sparing platform establishes an adaptable framework for next-generation broadly-protective vaccines against rapidly-evolving viruses. Graphical
- Open Access
Hematopoietic stem cell conditioned media induces excessive mitochondrial fission via Drp-1 to target colorectal cancer
Mitochondria, often referred to as the “powerhouses of the cell,” are particularly crucial in cancer cells due to their high energy demands. Mitochondrial fusion-fission dynamics play a critical role in regulating signaling pathways and metabolic activities in colorectal cancer (CRC) cells. Increased mitochondrial fission drives metabolic reprogramming, enabling CRCs to proliferate, metastasize, and resist chemotherapy. Paradoxically, excessive fission induces mitochondria-mediated apoptosis. Our previous studies have shown that hematopoietic stem cell-derived conditioned media (CM) modulate the apoptosis pathway and mitochondrial bioenergetics of cancer stem cells by altering the cancer microenvironment. In this study, we found that HSCs-CM facilitates excessive fission in colorectal cancer cells by modulating Drp-1 and inducing the mitophagy-mediated apoptosis pathway, leading to the clearance of these cells. Moreover, proteomics data showed that HSCs-CM dysregulated the electron transport chain complexes, with an exceptionally high degree of dysregulation of complexes III and IV. Metabolomics and RNA sequencing revealed the dysregulation of critical proteins involved in mitochondrial bioenergetics and the autophagy pathway in CRCs treated with CM. Taken together, our studies reveal the therapeutic potential of HSC-conditioned media for treating colorectal cancer. Highlights: Hematopoietic stem cell-derived conditioned media induced excessive mitochondrial fission by upregulating the Drp-1 protein, leading to the upregulation of the apoptosis pathway and cell death. The excessive mitochondrial fission and bioenergetic dysfunction induced by HSCs-CM result in a loss of mitochondrial membrane potential (MMP) and high reactive oxygen species (ROS) production HSCs-CM severely disrupt mitochondrial bioenergetics in CRC cells, leading to an energy crisis and promoting the PINK-1 mediated mitophagy pathway.
Open AccessHematopoietic stem cell conditioned media induces excessive mitochondrial fission via Drp-1 to target colorectal cancer
Mitochondria, often referred to as the “powerhouses of the cell,” are particularly crucial in cancer cells due to their high energy demands. Mitochondrial fusion-fission dynamics play a critical role in regulating signaling pathways and metabolic activities in colorectal cancer (CRC) cells. Increased mitochondrial fission drives metabolic reprogramming, enabling CRCs to proliferate, metastasize, and resist chemotherapy. Paradoxically, excessive fission induces mitochondria-mediated apoptosis. Our previous studies have shown that hematopoietic stem cell-derived conditioned media (CM) modulate the apoptosis pathway and mitochondrial bioenergetics of cancer stem cells by altering the cancer microenvironment. In this study, we found that HSCs-CM facilitates excessive fission in colorectal cancer cells by modulating Drp-1 and inducing the mitophagy-mediated apoptosis pathway, leading to the clearance of these cells. Moreover, proteomics data showed that HSCs-CM dysregulated the electron transport chain complexes, with an exceptionally high degree of dysregulation of complexes III and IV. Metabolomics and RNA sequencing revealed the dysregulation of critical proteins involved in mitochondrial bioenergetics and the autophagy pathway in CRCs treated with CM. Taken together, our studies reveal the therapeutic potential of HSC-conditioned media for treating colorectal cancer. Highlights: Hematopoietic stem cell-derived conditioned media induced excessive mitochondrial fission by upregulating the Drp-1 protein, leading to the upregulation of the apoptosis pathway and cell death. The excessive mitochondrial fission and bioenergetic dysfunction induced by HSCs-CM result in a loss of mitochondrial membrane potential (MMP) and high reactive oxygen species (ROS) production HSCs-CM severely disrupt mitochondrial bioenergetics in CRC cells, leading to an energy crisis and promoting the PINK-1 mediated mitophagy pathway.
- 15 September 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (18) , e71036
Arachidonic Acid Protects Skeletal Muscle Against Hyperglycaemia‐Induced Muscle Atrophy by Modulating Myogenesis and Regulating KLF15 Expression in C57Bl /6 Mice
Glucotoxicity or hyperglycemia as a consequence of Type 1 diabetes affects numerous tissues, including skeletal muscles, and translates to muscle wasting or atrophy. Since 40% of the total body weight comprises skeletal muscles, and because this tissue plays an essential role in voluntary movement, protecting its integrity is crucial for maintaining whole‐body homeostasis. Although different studies have investigated the role of arachidonic acid (AA) in salvaging skeletal muscle atrophy, the underlying mechanisms concerning the activation of muscle stem cells and the regenerative process need further elucidation. In this study, we use a streptozotocin‐induced Type 1 diabetes mouse model to study the effects of AA in mitigating the reduction in the myogenesis process and also try to elaborate on the anti‐atrophic and anti‐inflammatory properties of AA, which help to rescue the levels of sarcomeric protein. To carry out this study, male C57BL/6 mice (5‐week‐old) were divided into Control, diabetic (STZ) and AA‐administered diabetic (STZ + AA) groups ( n = 6 mice per group). The study involved a short‐term treatment regime of 5 days. Muscle stem cell activation, inflammation, and muscle fiber integrity were assessed using molecular techniques. A global proteomic study provided insights into differential protein expression status. Histological analysis revealed the rescue of muscle cells at different stages of myogenesis and fiber integrity upon AA administration in diabetic mice. Moreover, the proteomic results supported the upregulation of stemness upon AA treatment as well. Additionally, it also showed the rescue of the sarcomeric protein repertoire. The findings suggest that AA holds myogenic properties, which stem from its role in activating the muscle stem cells, and this can be used as a potential therapeutic supplement for diabetic patients.
- 15 September 2025
- Published by Wiley in The FASEB Journal
- Vol. 39 (18) , e71036
Arachidonic Acid Protects Skeletal Muscle Against Hyperglycaemia‐Induced Muscle Atrophy by Modulating Myogenesis and Regulating KLF15 Expression in C57Bl /6 Mice
Glucotoxicity or hyperglycemia as a consequence of Type 1 diabetes affects numerous tissues, including skeletal muscles, and translates to muscle wasting or atrophy. Since 40% of the total body weight comprises skeletal muscles, and because this tissue plays an essential role in voluntary movement, protecting its integrity is crucial for maintaining whole‐body homeostasis. Although different studies have investigated the role of arachidonic acid (AA) in salvaging skeletal muscle atrophy, the underlying mechanisms concerning the activation of muscle stem cells and the regenerative process need further elucidation. In this study, we use a streptozotocin‐induced Type 1 diabetes mouse model to study the effects of AA in mitigating the reduction in the myogenesis process and also try to elaborate on the anti‐atrophic and anti‐inflammatory properties of AA, which help to rescue the levels of sarcomeric protein. To carry out this study, male C57BL/6 mice (5‐week‐old) were divided into Control, diabetic (STZ) and AA‐administered diabetic (STZ + AA) groups ( n = 6 mice per group). The study involved a short‐term treatment regime of 5 days. Muscle stem cell activation, inflammation, and muscle fiber integrity were assessed using molecular techniques. A global proteomic study provided insights into differential protein expression status. Histological analysis revealed the rescue of muscle cells at different stages of myogenesis and fiber integrity upon AA administration in diabetic mice. Moreover, the proteomic results supported the upregulation of stemness upon AA treatment as well. Additionally, it also showed the rescue of the sarcomeric protein repertoire. The findings suggest that AA holds myogenic properties, which stem from its role in activating the muscle stem cells, and this can be used as a potential therapeutic supplement for diabetic patients.
- Open Access
- 23 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
PfPPM2 signalling regulates asexual division and sexual conversion of human malaria parasite Plasmodium falciparum
Malaria parasite undergoes interesting developmental transition in human and mosquito host. While it divides asynchronously in the erythrocytes, it switches to sexual forms, which is critical for disease transmission. We report a novel signalling pathway involving Protein Phosphatase PfPPM2, which regulates asexual division of Plasmodium falciparum as well as its conversion to sexual forms. PfPPM2 may regulate the phosphorylation of key proteins involved in chromatin remodelling and protein translation. One of the key PfPPM2-targets was Heterochromatin Protein 1 (HP1), a regulator of heritable gene silencing which contributes to both mitotic proliferation as well as sexual commitment of the parasite. PfPPM2 promotes sexual conversion by regulating the interaction between HP1, H3K9me3 and chromatin and it achieves this by dephosphorylating S33 of HP1. PfPPM2 also regulates protein synthesis in the parasite by repressing the phosphorylation of initiation factor eIF2α, which is likely to contribute to parasite division and possibly sexual differentiation.
- 23 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessPfPPM2 signalling regulates asexual division and sexual conversion of human malaria parasite Plasmodium falciparum
Malaria parasite undergoes interesting developmental transition in human and mosquito host. While it divides asynchronously in the erythrocytes, it switches to sexual forms, which is critical for disease transmission. We report a novel signalling pathway involving Protein Phosphatase PfPPM2, which regulates asexual division of Plasmodium falciparum as well as its conversion to sexual forms. PfPPM2 may regulate the phosphorylation of key proteins involved in chromatin remodelling and protein translation. One of the key PfPPM2-targets was Heterochromatin Protein 1 (HP1), a regulator of heritable gene silencing which contributes to both mitotic proliferation as well as sexual commitment of the parasite. PfPPM2 promotes sexual conversion by regulating the interaction between HP1, H3K9me3 and chromatin and it achieves this by dephosphorylating S33 of HP1. PfPPM2 also regulates protein synthesis in the parasite by repressing the phosphorylation of initiation factor eIF2α, which is likely to contribute to parasite division and possibly sexual differentiation.
- Open Access
- 25 March 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
Mapping growth differentiation factor-15 (GDF15)-mediated signaling pathways in cancer: insights into its role across different cancer types
Growth differentiation factor-15 (GDF15) is a cytokine/growth factor that belongs to the Transforming growth factor-ß (TGF-ß) protein family. The expression of GDF15 is low in most human organs under normal conditions. GDF15 is a stress-responsive cytokine primarily produced by macrophages in response to inflammatory stimuli. The altered expression of GDF15 is associated with many cancers due to the inflammation caused by the disease. GDF15 triggers the activity through its receptor Glial-derived neurotrophic factor-family receptor α-like (GFRAL) and mediates multiple downstream signaling cascades, which are involved in the progression of cancers. Considering the biological importance of GDF15 in different cancers, we applied data mining techniques to systematically compile and analyze the signaling events associated with GDF15 using NetPath criteria. This resulted in constructing a detailed GDF15-mediated signaling pathway map, enhancing our understanding of its molecular mechanisms in cancer. Furthermore, proteins linked to colorectal and breast cancer identified in our pathway map were cross-referenced with established cancer pathway databases to identify unannotated proteins, highlighting gaps in the current annotations. To investigate potential therapeutic strategies, we performed molecular docking simulations and identified Vitisifuran B as a novel inhibitor that could block the GDF15-GFRAL interaction. These findings suggest that Vitisifuran B could effectively modulate GDF15 signaling, offering a promising avenue for cancer therapeutics. This study underscores the power of computational approaches, such as data mining and molecular docking, in enhancing our understanding of GDF15 signaling in cancer and identifying potential inhibitors for therapeutic development.
- 25 March 2025
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-15
Open AccessMapping growth differentiation factor-15 (GDF15)-mediated signaling pathways in cancer: insights into its role across different cancer types
Growth differentiation factor-15 (GDF15) is a cytokine/growth factor that belongs to the Transforming growth factor-ß (TGF-ß) protein family. The expression of GDF15 is low in most human organs under normal conditions. GDF15 is a stress-responsive cytokine primarily produced by macrophages in response to inflammatory stimuli. The altered expression of GDF15 is associated with many cancers due to the inflammation caused by the disease. GDF15 triggers the activity through its receptor Glial-derived neurotrophic factor-family receptor α-like (GFRAL) and mediates multiple downstream signaling cascades, which are involved in the progression of cancers. Considering the biological importance of GDF15 in different cancers, we applied data mining techniques to systematically compile and analyze the signaling events associated with GDF15 using NetPath criteria. This resulted in constructing a detailed GDF15-mediated signaling pathway map, enhancing our understanding of its molecular mechanisms in cancer. Furthermore, proteins linked to colorectal and breast cancer identified in our pathway map were cross-referenced with established cancer pathway databases to identify unannotated proteins, highlighting gaps in the current annotations. To investigate potential therapeutic strategies, we performed molecular docking simulations and identified Vitisifuran B as a novel inhibitor that could block the GDF15-GFRAL interaction. These findings suggest that Vitisifuran B could effectively modulate GDF15 signaling, offering a promising avenue for cancer therapeutics. This study underscores the power of computational approaches, such as data mining and molecular docking, in enhancing our understanding of GDF15 signaling in cancer and identifying potential inhibitors for therapeutic development.
- Open Access
- 27 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Development of pathophysiologically relevant models of sickle cell disease and β-thalassemia for therapeutic studies
Ex vivo cellular system that accurately replicates sickle cell disease and β-thalassemia characteristics is a highly sought-after goal in the field of erythroid biology. In this study, we present the generation of erythroid progenitor lines with sickle cell disease and β-thalassemia mutation using CRISPR/Cas9. The disease cellular models exhibit similar differentiation profiles, globin expression and proteome dynamics as patient-derived hematopoietic stem/progenitor cells. Additionally, these cellular models recapitulate pathological conditions associated with both the diseases. Hydroxyurea and pomalidomide treatment enhanced fetal hemoglobin levels. Notably, we introduce a therapeutic strategy for the above diseases by recapitulating the HPFH3 genotype, which reactivates fetal hemoglobin levels and rescues the disease phenotypes, thus making these lines a valuable platform for studying and developing new therapeutic strategies. Altogether, we demonstrate our disease cellular systems are physiologically relevant and could prove to be indispensable tools for disease modeling, drug screenings and cell and gene therapy-based applications.
- 27 February 2024
- Published by Springer Nature in Nature Communications
- Vol. 15 (1) , 1-18
Open AccessDevelopment of pathophysiologically relevant models of sickle cell disease and β-thalassemia for therapeutic studies
Ex vivo cellular system that accurately replicates sickle cell disease and β-thalassemia characteristics is a highly sought-after goal in the field of erythroid biology. In this study, we present the generation of erythroid progenitor lines with sickle cell disease and β-thalassemia mutation using CRISPR/Cas9. The disease cellular models exhibit similar differentiation profiles, globin expression and proteome dynamics as patient-derived hematopoietic stem/progenitor cells. Additionally, these cellular models recapitulate pathological conditions associated with both the diseases. Hydroxyurea and pomalidomide treatment enhanced fetal hemoglobin levels. Notably, we introduce a therapeutic strategy for the above diseases by recapitulating the HPFH3 genotype, which reactivates fetal hemoglobin levels and rescues the disease phenotypes, thus making these lines a valuable platform for studying and developing new therapeutic strategies. Altogether, we demonstrate our disease cellular systems are physiologically relevant and could prove to be indispensable tools for disease modeling, drug screenings and cell and gene therapy-based applications.
- 1 December 2022
- Published by Wiley in Journal of Cell Communication and Signaling
- Vol. 17 (3) , 1081-1088
A network map of discoidin domain receptor 1(DDR1)-mediated signaling in pathological conditions
- 1 December 2022
- Published by Wiley in Journal of Cell Communication and Signaling
- Vol. 17 (3) , 1081-1088
A network map of discoidin domain receptor 1(DDR1)-mediated signaling in pathological conditions